STOCK TITAN

BETTERLIFE PHARMA INC - BETRF STOCK NEWS

Welcome to our dedicated page for BETTERLIFE PHARMA news (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on BETTERLIFE PHARMA stock.

BETTERLIFE PHARMA INC (BETRF) is a pharmaceutical company dedicated to developing innovative therapies for mental health disorders and neurological conditions. With a focus on research and development, the company is at the forefront of advancements in treatment options. BETRF's strong financial position and strategic partnerships enhance its ability to bring novel products to market.

Rhea-AI Summary

BetterLife Pharma has appointed Mr. Henri Sant-Cassia to its Board of Directors, enhancing its leadership in the psychedelic medicine sector. Sant-Cassia, a veteran in plant medicine and co-founder of The Conscious Fund, brings a decade of experience and a strong network. His past successes include generating over $200 million in company valuations. Alongside his appointment, the company announces the resignation of Mr. Sergei Stetsenko. The new leadership aims to accelerate the development of non-hallucinogenic compounds targeting mental health disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.97%
Tags
management
-
Rhea-AI Summary

BetterLife Pharma Inc. closed a non-brokered private placement, issuing 1,142,857 common shares at USD$0.70 each for total proceeds of USD$800,000. These funds will support working capital and advance pre-clinical and clinical programs. The shares issued are subject to a four-month hold period. BetterLife is a biotechnology company focused on developing psychedelic treatments for mental disorders and interferon-based technologies to combat viral infections like COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.86%
Tags
none
-
Rhea-AI Summary

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) has applied for patent protection for its innovative implantable subcutaneous product aimed at preventing psychedelic drug diversion. This device addresses the risk of patients self-administering full doses of controlled substances like LSD and psilocybin instead of prescribed microdoses. The product includes options for controlled release, potentially reducing healthcare costs and improving patient compliance. CEO Ahmad Doroudian emphasized its importance in mitigating risks associated with psychedelic treatments, promoting safer use in mental health therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.87%
Tags
none
Rhea-AI Summary

BetterLife Pharma announced the appointment of Dr. Thomas Laughren as a Regulatory Advisor. Dr. Laughren, a former FDA Director of Psychiatry Products, brings extensive experience in psychiatric drug development. CEO Dr. Ahmad Doroudian expressed excitement about this addition, noting it will enhance their IND-enabling activities. BetterLife focuses on developing second-generation psychedelics for neuro-psychiatric disorders, alongside interferon-based technologies targeting viral infections like COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
none
-
Rhea-AI Summary

BetterLife Pharma Inc. announced its inclusion in the Horizons Psychedelic Stock Index ETF, providing significant exposure to investors in the psychedelics sector. The Company closed a non-brokered private placement, issuing 1,779,833 common shares at CAD$1.40 each, raising CAD$2,491,766 for working capital and its therapeutic pipeline, which includes TD-0148A, a second-generation LSD derivative aimed at treating severe depression, PTSD, and migraines. CEO Ahmad Doroudian highlighted the ETF's potential to attract new investors and enhance shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
none
-
Rhea-AI Summary

BetterLife Pharma has announced a research agreement with the laboratory of Dr. Adam L. Halberstadt at UCSD to explore TD-0148A, a non-hallucinogenic derivative of LSD, for the treatment of severe treatment-resistant depression and PTSD. The collaboration aims to leverage Dr. Halberstadt's expertise in psychedelic pharmacology to evaluate TD-0148A's potential in preclinical behavioral studies. This development aligns with BetterLife's focus on addressing the unmet needs in mental health treatments, reflecting a strategic push into innovative therapeutic solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Rhea-AI Summary

BetterLife Pharma Inc. announced a partnership with Pontificia Universidad Católica de Chile to initiate a randomized, placebo-controlled trial named IN2COVID in Q2 2021. The study aims to evaluate the effectiveness of Altum Pharmaceuticals' inhaled interferon alpha-2b product, AP-003, in treating COVID-19 patients. Preclinical studies suggest that interferon alpha-2b may enhance viral clearance. The trial will consist of two phases: a Phase 1 trial in healthy subjects and a Phase 2 trial in early-stage COVID-19 patients, potentially concluding by Q3 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
covid-19
-
Rhea-AI Summary

BetterLife Pharma Inc. has partnered with Carleton University to research TD-0148A, a novel LSD derivative aimed at treating mental health disorders like severe depression and PTSD. This second-generation molecule is designed to deliver therapeutic effects without the psychoactive side effects typical of traditional LSD. The collaboration leverages Carleton's expertise in neuroscience to accelerate the research process and potentially bring this therapy to clinical trials. The company's focus aligns with addressing the significant unmet needs in psychiatric treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
-
Rhea-AI Summary

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced a partnership with Eurofins CDMO Alphora Inc. for GMP manufacturing of its second-generation LSD derivative, TD-0148A. This treatment aims to address major depressive disorders while minimizing psychoactive side effects. The manufacturing takes place in Mississauga, Ontario, utilizing a proprietary process that avoids controlled substances. Dr. Ahmad Doroudian emphasized the significance of this collaboration for rapidly advancing the drug's development towards regulatory submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
none
Rhea-AI Summary

BetterLife Pharma has announced its participation in the Emerging Growth Conference on February 17, 2021, inviting individual and institutional investors to a real-time, interactive presentation. The company's CEO, Dr. Ahmad Doroudian, will present BetterLife’s plans at 2:30 PM Eastern for 30 minutes, followed by a Q&A session. The event allows for direct interaction with shareholders and the investment community. An archived version will be available post-event. For more details, visit BetterLife's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.28%
Tags
conferences

FAQ

What is the current stock price of BETTERLIFE PHARMA (BETRF)?

The current stock price of BETTERLIFE PHARMA (BETRF) is $0.07527 as of December 20, 2024.

What is the market cap of BETTERLIFE PHARMA (BETRF)?

The market cap of BETTERLIFE PHARMA (BETRF) is approximately 10.1M.

What is the core focus of BETTERLIFE PHARMA INC?

BETRF focuses on developing innovative therapies for mental health disorders and neurological conditions.

What sets BETRF apart from other pharmaceutical companies?

BETRF's strong emphasis on research and development, as well as strategic partnerships, distinguishes it in the industry.

How can I contact Investor Relations at BETRF?

You can reach out to David Melles, Investor Relations Manager, at David.Melles@blifepharma.com or call 1-778-887-1928.

Does BETRF have any recent achievements?

BETRF is known for its advancements in treatment options for mental health disorders and neurological conditions, reflecting its commitment to innovation.

What is the goal of BETTERLIFE PHARMA INC?

BETRF aims to improve the quality of life for individuals affected by mental health disorders through the development of cutting-edge therapies.

How can I stay informed about BETRF's latest developments?

Keep up to date with the latest news and updates from BETRF to stay informed about their progress in the pharmaceutical industry.

Is BETRF actively involved in research and development?

Yes, BETRF places a strong emphasis on R&D to drive innovation and bring novel products to the market.

What are some of BETRF's strategic partnerships?

BETRF collaborates with key partners to enhance its capabilities in developing and commercializing new therapies for mental health disorders.

Where is BETTERLIFE PHARMA INC headquartered?

BETRF is headquartered in a key location, allowing it to access top talent and resources in the pharmaceutical industry.

What is the vision of BETTERLIFE PHARMA INC?

BETRF envisions a future where individuals have access to advanced treatments that significantly improve their mental health and well-being.

BETTERLIFE PHARMA INC

OTC:BETRF

BETRF Rankings

BETRF Stock Data

10.12M
92.71M
27.53%
Biotechnology
Healthcare
Link
United States of America
Vancouver